GleamWall
中文EN

SER Serina Therapeutics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1708599 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY132.1%
TTM net income YoY-72.2%
TTM EPS YoY-26.5%
Revenue 3-yr CAGR56.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-18,478.5%
Net margin-14,755.4%
FCF margin-13,856.9%
EBITDA margin-18,439.2%

Returns

ROE-6,351.7%
ROA-280.5%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets100.5%
Debt / equity—
Current ratio1.71x
Interest coverage-112.78x

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue45.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$130,000$56,000
R&D expense$13.15M$7.48M
SG&A expense$11.00M$9.62M
Operating income-$24.02M-$17.05M
Interest expense$213,000$526,000
Pretax income-$19.20M-$11.21M
Income tax$18,000$0
Net income-$19.18M-$11.14M
EBITDA-$23.92M-$16.95M
EPS (basic)-1.91-1.51
EPS (diluted)-1.91-1.51
Weighted avg. shares (diluted)10.19M7.36M
Balance sheet
Cash & equivalents$3.06M$3.67M
Current assets$6.08M$5.68M
PP&E, net$465,000$501,000
Total assets$6.95M$6.72M
Current liabilities$3.56M$2.37M
Total liabilities$6.99M$6.22M
Shareholders' equity-$37,000$641,000
Shares outstanding10.77M9.42M
Cash flow statement
Operating cash flow-$17.95M-$17.14M
Capital expenditure$59,000$22,000
Free cash flow-$18.01M-$17.16M
Investing cash flow-$59,000-$22,000
Financing cash flow$17.41M$13.21M
Depreciation & amortization$100,000$100,000
Stock-based compensation$3.79M$2.60M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.